

PRELIMINARY DATA ON THE EFFICACY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN A 'REAL-WORLD' CLINICAL SETTING

Olga Giouleme

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

Real-world Greek multicenter study of 101 ulcerative colitis patients treated with ustekinumab shows 72% clinical response and 46% steroid-free remission at week 16 following induction, predominantly in biologic-experienced patients.

KEY POINTS

- Among 50 patients with active disease and adequate data at week 16, clinical response was achieved in 36 patients (72%) and clinical steroid-free remission in 23 patients (46%)
- The majority of patients (76%) had been exposed to at least one prior biologic agent, most commonly anti-TNFs (54%), with ustekinumab used predominantly as second or third line therapy
- Concomitant use of 5-ASA was associated with higher probability of clinical response at week 16 ($P=0.009$), while hemoglobin greater than 13.1 g/dL ($P=0.047$) and age greater than 60 years ($P=0.059$) were associated with lower probability of response
- The induction regimen consisted of intravenous loading at 6 mg/kg plus first 90 mg subcutaneous injection at week 8, with only 4 patients discontinuing due to no response

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/bf449120-743b-11ee-8180-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.